1. Home
  2. HYI vs INO Comparison

HYI vs INO Comparison

Compare HYI & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset High Yield Defined Opportunity Fund Inc.

HYI

Western Asset High Yield Defined Opportunity Fund Inc.

N/A

Current Price

$9.59

Market Cap

135.2M

Sector

Finance

ML Signal

N/A

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

N/A

Current Price

$0.61

Market Cap

118.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYI
INO
Founded
2010
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.2M
118.9M
IPO Year
2010
1999

Fundamental Metrics

Financial Performance
Metric
HYI
INO
Price
$9.59
$0.61
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $3.17
AVG Volume (30 Days)
83.8K
★ 3.7M
Earning Date
01-01-0001
11-13-2026
Dividend Yield
★ 9.59%
N/A
EPS Growth
N/A
★ 54.18
EPS
★ N/A
N/A
Revenue
N/A
★ $42,220,086.00
Revenue This Year
N/A
$920.26
Revenue Next Year
N/A
$7,490.76
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 19.37
52 Week Low
$9.42
$0.56
52 Week High
$11.41
$2.72

Technical Indicators

Market Signals
Indicator
HYI
INO
Relative Strength Index (RSI) 39.67 27.34
Support Level $9.42 $0.56
Resistance Level $10.66 $1.23
Average True Range (ATR) 0.11 0.14
MACD 0.02 -0.03
Stochastic Oscillator 52.80 0.84

Price Performance

Historical Comparison
HYI
INO

About HYI Western Asset High Yield Defined Opportunity Fund Inc.

Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Share on Social Networks: